These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 26673822)

  • 1. A tyrosine phosphatase SHP2 gain-of-function mutation enhances malignancy of breast carcinoma.
    Hu Z; Wang X; Fang H; Liu Y; Chen D; Zhang Q; Liu X; Wei D; Qu C; Wang S
    Oncotarget; 2016 Feb; 7(5):5664-76. PubMed ID: 26673822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SHP2 promotes laryngeal cancer growth through the Ras/Raf/Mek/Erk pathway and serves as a prognostic indicator for laryngeal cancer.
    Gu J; Han T; Ma RH; Zhu YL; Jia YN; Du JJ; Chen Y; Jiang XJ; Xie XD; Guo X
    Int J Oncol; 2014 Feb; 44(2):481-90. PubMed ID: 24297342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shp2 Plays a Critical Role in IL-6-Induced EMT in Breast Cancer Cells.
    Sun X; Zhang J; Wang Z; Ji W; Tian R; Zhang F; Niu R
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of SHP2 tyrosine phosphatase promotes the tumorigenesis of breast carcinoma.
    Hu Z; Fang H; Wang X; Chen D; Chen Z; Wang S
    Oncol Rep; 2014 Jul; 32(1):205-12. PubMed ID: 24858400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Excitatory neuron-specific SHP2-ERK signaling network regulates synaptic plasticity and memory.
    Ryu HH; Kim T; Kim JW; Kang M; Park P; Kim YG; Kim H; Ha J; Choi JE; Lee J; Lim CS; Kim CH; Kim SJ; Silva AJ; Kaang BK; Lee YS
    Sci Signal; 2019 Mar; 12(571):. PubMed ID: 30837304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring the effect of D61G mutation on SHP2 cause gain of function activity by a molecular dynamics study.
    Li HL; Ma Y; Zheng CJ; Jin WY; Liu WS; Wang RL
    J Biomol Struct Dyn; 2018 Nov; 36(14):3856-3868. PubMed ID: 29125030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Shp2 SUMOylation promotes ERK activation and hepatocellular carcinoma development.
    Deng R; Zhao X; Qu Y; Chen C; Zhu C; Zhang H; Yuan H; Jin H; Liu X; Wang Y; Chen Q; Huang J; Yu J
    Oncotarget; 2015 Apr; 6(11):9355-69. PubMed ID: 25823821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Noonan syndrome-causing SHP2 mutants inhibit insulin-like growth factor 1 release via growth hormone-induced ERK hyperactivation, which contributes to short stature.
    De Rocca Serra-Nédélec A; Edouard T; Tréguer K; Tajan M; Araki T; Dance M; Mus M; Montagner A; Tauber M; Salles JP; Valet P; Neel BG; Raynal P; Yart A
    Proc Natl Acad Sci U S A; 2012 Mar; 109(11):4257-62. PubMed ID: 22371576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
    Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
    Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SHP2E76K mutant promotes lung tumorigenesis in transgenic mice.
    Schneeberger VE; Luetteke N; Ren Y; Berns H; Chen L; Foroutan P; Martinez GV; Haura EB; Chen J; Coppola D; Wu J
    Carcinogenesis; 2014 Aug; 35(8):1717-25. PubMed ID: 24480804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation.
    Fragale A; Tartaglia M; Wu J; Gelb BD
    Hum Mutat; 2004 Mar; 23(3):267-77. PubMed ID: 14974085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SHP2 promotes proliferation of breast cancer cells through regulating Cyclin D1 stability
    Yuan Y; Fan Y; Gao Z; Sun X; Zhang H; Wang Z; Cui Y; Song W; Wang Z; Zhang F; Niu R
    Cancer Biol Med; 2020 Aug; 17(3):707-725. PubMed ID: 32944401
    [No Abstract]   [Full Text] [Related]  

  • 13. Beta4 integrin activates a Shp2-Src signaling pathway that sustains HGF-induced anchorage-independent growth.
    Bertotti A; Comoglio PM; Trusolino L
    J Cell Biol; 2006 Dec; 175(6):993-1003. PubMed ID: 17158954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PCC0208023, a potent SHP2 allosteric inhibitor, imparts an antitumor effect against KRAS mutant colorectal cancer.
    Chen X; Zou F; Hu Z; Du G; Yu P; Wang W; Wang H; Ye L; Tian J
    Toxicol Appl Pharmacol; 2020 Jul; 398():115019. PubMed ID: 32335126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The gain-of-function mutation E76K in SHP2 promotes CAC tumorigenesis and induces EMT via the Wnt/β-catenin signaling pathway.
    Zhang Q; Li Y; Zhao R; Wang X; Fan C; Xu Y; Liu Y; Li J; Wang S
    Mol Carcinog; 2018 May; 57(5):619-628. PubMed ID: 29323748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gab1, SHP2, and protein kinase A are crucial for the activation of the endothelial NO synthase by fluid shear stress.
    Dixit M; Loot AE; Mohamed A; Fisslthaler B; Boulanger CM; Ceacareanu B; Hassid A; Busse R; Fleming I
    Circ Res; 2005 Dec; 97(12):1236-44. PubMed ID: 16284184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Q510E mutation in Shp2 perturbs heart valve development by increasing cell migration.
    Edwards MA; Crombie K; Schramm C; Krenz M
    J Appl Physiol (1985); 2015 Jan; 118(1):124-31. PubMed ID: 25359717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allosteric Inhibition of SHP2 Stimulates Antitumor Immunity by Transforming the Immunosuppressive Environment.
    Quintana E; Schulze CJ; Myers DR; Choy TJ; Mordec K; Wildes D; Shifrin NT; Belwafa A; Koltun ES; Gill AL; Singh M; Kelsey S; Goldsmith MA; Nichols R; Smith JAM
    Cancer Res; 2020 Jul; 80(13):2889-2902. PubMed ID: 32350067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo.
    Grosskopf S; Eckert C; Arkona C; Radetzki S; Böhm K; Heinemann U; Wolber G; von Kries JP; Birchmeier W; Rademann J
    ChemMedChem; 2015 May; 10(5):815-26. PubMed ID: 25877780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functions of Shp2 in cancer.
    Zhang J; Zhang F; Niu R
    J Cell Mol Med; 2015 Sep; 19(9):2075-83. PubMed ID: 26088100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.